AVAX
SPRO icon

Atlas Venture Associates XI’s Spero Therapeutics SPRO Stock Holding History

Atlas Venture Associates XI’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$26.7M Buy
+1,376,968
New +$21.5M 4.23% 4

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Atlas Venture Associates XI's SPRO Position: Q4 2020 in Review

Atlas Venture Associates XI opened a new position in Spero Therapeutics (SPRO) in Q4 2020: 1,376,968 shares worth $26.7M. The stake represents 4.23% of the portfolio and ranks #4 among its holdings.

89 funds tracked by Wall St. Rank hold SPRO as of Q4 2020.

  • Atlas Venture Associates XI held 1,376,968 shares of Spero Therapeutics worth $26.7M as of Q4 2020.
  • Spero Therapeutics was a new Atlas Venture Associates XI position in Q4 2020.
  • Spero Therapeutics made up 4.23% of Atlas Venture Associates XI's portfolio in Q4 2020, its #4 holding.
  • 89 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2020.

Based on Atlas Venture Associates XI's 13F filing for Q4 2020, filed 1 Feb 2021.